HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egea Biosciences Inc.

Division of Johnson & Johnson
www.egeabiosciences.com

Latest From Egea Biosciences Inc.

JJDC Strategy Emphasizes the J & the J

Under the leadership of new president David Holveck, Johnson & Johnson Development Corp. is aligning its strategy more closely with the needs and wants of J&J's many companies.
Strategy Business Strategies

The Buzz at JP Morgan--Biopharma: New Models Wanted

Perhaps the loudest message from the biopharmaceutical side of the JP Morgan conference was: "Change the Big Pharma model." The theme was pervasive-in discussions of the most interesting products; among the biotechs; indeed in the Big Pharma presentations themselves.
BioPharmaceutical Strategy

The Better Exit for Private Biotechs: M&A

Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend? Yes--and a real change in thinking at Big Pharma and among VCs.
Business Strategies

Big Pharma's Large Molecule Challenge

Several of the most small molecule-minded of drug firms have recently made significant moves to increase their macromolecule activities. They now face the formidable task of quickly building the specialized capabilities needed to compete with the more well-entrenched large-molecule players. These relative newcomers vary in their levels of commitment and approaches--from those building or acquiring substantial in-house capabilities and looking to develop biomolecules across a wide range of therapeutic areas to others who favor dealmaking to acquire protein drugs.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Glen A Evans, MD, PhD, CEO
    Tod Lauerman, PhD, SVP, Bus. Dev.
    Steven Richieri, SVP, Reg. Affairs & Prod. Dev.
  • Contact Info
  • Egea Biosciences Inc.
    Phone: (858) 554-1805
    6759 Mesa Ridge Rd., Ste. 100
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register